Opus Genetics (IRD) Change in Account Payables (2020 - 2026)
Opus Genetics (IRD) reported Change in Account Payables of $1.2 million for Q1 2026, up 260.86% year-over-year from $320065.6 in Q1 2025, and up 43.66% on a QoQ basis from $804000.0 in Q4 2025.
Opus Genetics (IRD) has 7 years of Change in Account Payables data on file, last reported at $1.2 million in Q1 2026.
- Quarterly Change in Account Payables rose 260.86% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (up 559.66% YoY) and the FY2025 annual result came in at $7000.0, down 96.82% from the prior year.
- Change in Account Payables rose to $1.2 million in Q1 2026 per IRD's latest filing, from $804000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $1.5 million in Q4 2024 and bottomed at -$1.4 million in Q2 2024.
- The 5-year median for Change in Account Payables is $102000.0 (2023), against an average of $114647.1.
- The widest annual swing landed in 2023, when Change in Account Payables soared 23140.0%; it then plunged 1501.96% in 2024.
- Tracing IRD's Change in Account Payables over 5 years: stood at -$390000.0 in 2022, then surged by 195.64% to $373000.0 in 2023, then surged by 312.6% to $1.5 million in 2024, then plunged by 47.76% to $804000.0 in 2025, then soared by 43.66% to $1.2 million in 2026.
- Per Business Quant, the three latest IRD Change in Account Payables figures stand at $1.2 million (Q1 2026), $804000.0 (Q4 2025), and $906000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -3.26 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 35.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.16 Mn |
| Mar 31, 2026 | 1.16 Mn |
| Dec 31, 2025 | 804,000.00 |
| Dec 31, 2025 | 804,000.00 |
| Sep 30, 2025 | 906,000.00 |
| Sep 30, 2025 | 906,000.00 |
| Jun 30, 2025 | -985,000.00 |
| Jun 30, 2025 | -985,000.00 |
| Mar 31, 2025 | -718,000.00 |
| Mar 31, 2025 | -718,000.00 |
| Dec 31, 2024 | 1.54 Mn |
| Dec 31, 2024 | 1.54 Mn |
| Sep 30, 2024 | 200,000.00 |
| Sep 30, 2024 | 200,000.00 |
| Jun 30, 2024 | -1.43 Mn |
| Jun 30, 2024 | -1.43 Mn |
| Mar 31, 2024 | -89,000.00 |
| Mar 31, 2024 | -89,000.00 |
| Dec 31, 2023 | 373,000.00 |
| Dec 31, 2023 | 373,000.00 |
| Sep 30, 2023 | -545,000.00 |
| Sep 30, 2023 | -545,000.00 |
| Jun 30, 2023 | 102,000.00 |
| Jun 30, 2023 | 102,000.00 |
| Mar 31, 2023 | 1.15 Mn |
| Mar 31, 2023 | 1.15 Mn |
| Dec 31, 2022 | -390,000.00 |
| Dec 31, 2022 | -390,000.00 |
| Sep 30, 2022 | -427,000.00 |
| Sep 30, 2022 | -427,000.00 |
| Jun 30, 2022 | 307,000.00 |
| Jun 30, 2022 | 307,000.00 |
| Mar 31, 2022 | -5,000.00 |
| Mar 31, 2022 | -5,000.00 |
| Dec 31, 2021 | 165,000.00 |
| Dec 31, 2021 | 165,000.00 |
| Sep 30, 2021 | 55,000.00 |
| Sep 30, 2021 | 55,000.00 |
| Jun 30, 2021 | -39,000.00 |
| Jun 30, 2021 | -39,000.00 |
| Mar 31, 2021 | 200,000.00 |
| Mar 31, 2021 | 200,000.00 |
| Dec 31, 2020 | 578,000.00 |
| Dec 31, 2020 | 578,000.00 |
| Sep 30, 2020 | 36,000.00 |
| Sep 30, 2020 | 36,000.00 |
| Jun 30, 2020 | 168,000.00 |
| Jun 30, 2020 | 168,000.00 |
| Mar 31, 2020 | 10,000.00 |
| Mar 31, 2020 | 10,000.00 |